These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
724 related articles for article (PubMed ID: 7565543)
41. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Mussini C; Pezzotti P; Antinori A; Borghi V; Monforte Ad; Govoni A; De Luca A; Ammassari A; Mongiardo N; Cerri MC; Bedini A; Beltrami C; Ursitti MA; Bini T; Cossarizza A; Esposito R; Clin Infect Dis; 2003 Mar; 36(5):645-51. PubMed ID: 12594647 [TBL] [Abstract][Full Text] [Related]
42. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568 [TBL] [Abstract][Full Text] [Related]
43. PCP prophylaxis in perinatally HIV-exposed infant. Shahid SK Indian Pediatr; 2008 Nov; 45(11):939; discussion 939-40. PubMed ID: 19029576 [No Abstract] [Full Text] [Related]
44. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526 [TBL] [Abstract][Full Text] [Related]
45. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ; Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703 [TBL] [Abstract][Full Text] [Related]
46. Pneumocystis carinii pneumonia following discontinuation of primary prophylaxis despite highly active antiretroviral therapy. Mammen-Tobin A; Monteiro EF Int J STD AIDS; 2000 Jan; 11(1):64-5. PubMed ID: 10667904 [No Abstract] [Full Text] [Related]
47. Epidemiology of HIV/AIDS in women and children in the USA. Rogers MF Acta Paediatr Suppl; 1997 Jun; 421():15-6. PubMed ID: 9240851 [TBL] [Abstract][Full Text] [Related]
48. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Viani RM; Araneta MR; Deville JG; Spector SA Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789 [TBL] [Abstract][Full Text] [Related]
49. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators. Moorman AC; Von Bargen JC; Palella FJ; Holmberg SD J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):182-8. PubMed ID: 9768629 [TBL] [Abstract][Full Text] [Related]
50. Epidemiology of pediatric human immunodeficiency virus infection in the United States. Rogers MF; Caldwell MB; Gwinn ML; Simonds RJ Acta Paediatr Suppl; 1994 Aug; 400():5-7. PubMed ID: 7833562 [TBL] [Abstract][Full Text] [Related]
51. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. Kazanjian P; Locke AB; Hossler PA; Lane BR; Bartlett MS; Smith JW; Cannon M; Meshnick SR AIDS; 1998 May; 12(8):873-8. PubMed ID: 9631140 [TBL] [Abstract][Full Text] [Related]
52. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. Lundberg BE; Davidson AJ; Burman WJ AIDS; 2000 Nov; 14(16):2559-66. PubMed ID: 11101068 [TBL] [Abstract][Full Text] [Related]
53. Routinely available cotrimoxazole prophylaxis and occurrence of respiratory and diarrhoeal morbidity in infants born to HIV-infected mothers in South Africa. Coutsoudis A; Pillay K; Spooner E; Coovadia HM; Pembrey L; Newell ML S Afr Med J; 2005 May; 95(5):339-45. PubMed ID: 15931449 [TBL] [Abstract][Full Text] [Related]
54. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review. Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390 [TBL] [Abstract][Full Text] [Related]
55. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS. Payen MC; De Wit S; Sommereijns B; Clumeck N Biomed Pharmacother; 1997; 51(10):439-45. PubMed ID: 9863502 [TBL] [Abstract][Full Text] [Related]
57. Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Northern California Pediatric HIV Consortium. Maldonado YA; Araneta RG; Hersh AL Pediatr Infect Dis J; 1998 May; 17(5):398-402. PubMed ID: 9613653 [TBL] [Abstract][Full Text] [Related]
58. Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virus. Zar HJ; Dechaboon A; Hanslo D; Apolles P; Magnus KG; Hussey G Pediatr Infect Dis J; 2000 Jul; 19(7):603-7. PubMed ID: 10917216 [TBL] [Abstract][Full Text] [Related]
59. Evaluation and medical treatment of the HIV-exposed infant. American Academy of Pediatrics. Committee on Pediatric AIDS. Pediatrics; 1997 Jun; 99(6):909-17. PubMed ID: 9190556 [TBL] [Abstract][Full Text] [Related]
60. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]